Joshua MBA - VistaGen Therapeutics Sr Operations
| VTGN Stock | USD 2.60 0.13 4.76% |
Insider
Joshua MBA is Sr Operations of VistaGen Therapeutics
| Age | 53 |
| Address | 343 Allerton Avenue, South San Francisco, CA, United States, 94080 |
| Phone | 650 577 3600 |
| Web | https://www.vistagen.com |
VistaGen Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.394) % which means that it has lost $0.394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6152) %, meaning that it created substantial loss on money invested by shareholders. VistaGen Therapeutics' management efficiency ratios could be used to measure how well VistaGen Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, VistaGen Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 26th of November 2024, Return On Equity is likely to grow to 8.98, while Return On Tangible Assets are likely to drop (4.08). At this time, VistaGen Therapeutics' Net Tangible Assets are very stable compared to the past year. As of the 26th of November 2024, Debt To Assets is likely to grow to 0.24, while Deferred Long Term Asset Charges is likely to drop about 187.3 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Richard Hawkins | Lumos Pharma | 75 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| James JD | Eliem Therapeutics | 58 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Bradley JD | Lumos Pharma | 45 | |
| Lori CPA | Lumos Pharma | 40 | |
| Lisa Miller | Lumos Pharma | N/A | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| David MBA | Seres Therapeutics | 63 | |
| Jeff York | Seres Therapeutics | N/A | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.39 |
VistaGen Therapeutics Leadership Team
Elected by the shareholders, the VistaGen Therapeutics' board of directors comprises two types of representatives: VistaGen Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VistaGen. The board's role is to monitor VistaGen Therapeutics' management team and ensure that shareholders' interests are well served. VistaGen Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VistaGen Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Cynthia CPA, Chief Officer | ||
| Mark Ginski, Manufacturing Chemistry | ||
| Erik MD, Senior Pharmacovigilance | ||
| JD Esq, Chief Officer | ||
| Joshua MBA, Sr Operations | ||
| Jaakko MD, Senior Pharmacovigilance | ||
| Jessica JD, Assoc VP | ||
| III MD, Sr Operations | ||
| Shawn JD, CEO Director | ||
| Mark McPartland, Vice President - Corporate Development and Investor Relations | ||
| Trisha Fitzmaurice, Senior Resources | ||
| Mark Flather, Senior Markets |
VistaGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is VistaGen Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (77.74) % | ||||
| Current Valuation | (19.91 M) | ||||
| Shares Outstanding | 27.84 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 53.63 % | ||||
| Number Of Shares Shorted | 528.16 K | ||||
| Price To Earning | (0.66) X | ||||
| Price To Book | 0.82 X |
Pair Trading with VistaGen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with VistaGen Stock
Moving against VistaGen Stock
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Revenue Per Share 0.029 | Quarterly Revenue Growth (0.34) | Return On Assets (0.39) | Return On Equity (0.62) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.